Julie Rubinstein

Julie Rubinstein is the current President at Adaptive Biotechnologies. Julie has held various other positions at different companies including Senior Director, WW Commercial Development, Oncology Products at Pfizer from January 2010 to August 2010 and Director, WW Commercial Development, Oncology at Pfizer Pharmaceuticals from January 2001 to December 2009. Julie Rubinstein has also worked as a Market Development Manager at Johnson & Johnson from June 1999 to August 2001 and as a Marketing and Business Development at Collegiate Health Care from May 1995 to May 1997. Prior to their work in the healthcare industry, Rubinstein worked as a Financial Analyst in Morgan Stanley's Healthcare Group from August 1993 to May 1995.

Julie Rubinstein has an HBS from Harvard Business School, a BA from University of Pennsylvania, and a BSE from The Wharton School. Julie also attended Millburn High School.

Julie Rubinstein works with Susan Bobulsky - SVP, Diagnostics, clonoSEQ, Tycho Peterson - CFO, and Mark Adams - COO. Julie Rubinstein reports to Chad Robins, CEO, Co-Founder & Chairman.